RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

Public health officials reiterated the importance of vaccines after seeing a rise in circulating levels of respiratory syncytial virus (RSV).

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

This year's headlines on respiratory syncytial virus (RSV) focused largely on the relatively new vaccines -- including a new ...

The respiratory virus is the leading cause of hospitalisation for infants, with 12,000 babies admitted each year. Before next ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

In 2025, eligible pregnant women will be able to receive the respiratory syncytial virus (RSV) vaccine for free under the ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...

Earlier this week, British drugmaker GSK received approval in Canada for its RSV vaccine for adults aged between 50 and 59 ...